Opendata, web and dolomites

immunoassays SIGNED

Development of new immunoassays for the diagnosis and prediction of drug-related complement pathology

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 immunoassays project word cloud

Explore the words cloud of the immunoassays project. It provides you a very rough idea of what is the project "immunoassays" about.

formulations    quantitative    uuml    abs    attack    massive    irs    anaphylatoxins    hypersensitivity    adaptable    dr    patients    mediated    fda    iges    sometimes    membrane    nor    inflammatory    small    biomarker    elisa    release    carpa    severe    ema    regulatory    threatening    amplifying    ige    cleave    date    antibodies    proteins    events    industry    therapeutic    proteases    cascade    validated    cytokines    nanotechnology    blood    foreign    caused    models    animal    safety    published    allergies    molecules    stimulated    pseudoallergy    ouml    biomarkers    activation    proposes    hemocompatibility    innate    liposomes    cleavages    responds    mac    arise    reactions    initiate    globulin    infusion    regarding    pharmaceuticals    biologics    adverse    causing    hsrs    latter    immunoassays    nonclinical    cell    intravenous    class    evaluation    manner    requested    acute    immune    guidance    complement    life    fusion    medical    liposome    killing    allergy   

Project "immunoassays" data sheet

The following table provides information about the project.

Coordinator
TECODEVELOPMENT GMBH 

Organization address
address: MARIE-CURIE-STR. 1
city: RHEINBACH
postcode: 53359
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 174˙806 €
 EC max contribution 174˙806 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2022-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECODEVELOPMENT GMBH DE (RHEINBACH) coordinator 174˙806.00

Map

 Project objective

Infusion reactions (IRs) are complex, immune-mediated side effects, also known as hypersensitivity reactions (HSRs), that can occur upon intravenous infusion of pharmaceuticals, leading to severe and sometimes life-threatening conditions in patients. Those reactions may arise from a real allergy which is immune globulin class E (IgE) mediated or a “pseudoallergy”. The latter involves no IgEs and may arise because of activation of the complement (C) system called C activation-related pseudoallergy (CARPA). The complement (C-) system is part of the immune system called the innate immune system that is not adaptable and responds to foreign challenges in a non-specific manner. When stimulated proteases of the complement system cleave other C proteins and initiate an amplifying cascade of further cleavages. The end-result of this activation cascade is a massive acute inflammatory response caused by the release of cytokines, anaphylatoxins and the cell-killing membrane attack complex (MAC). Products triggering severe adverse events can include both traditional small molecules but also biologics such as therapeutic antibodies (Abs), fusion proteins, etc. and novel formulations using liposomes or nanotechnology. Regulatory guidance on the assessment of C-mediated infusion hypersensitivity has been published recently for the case of generic liposome production. Hemocompatibility (blood safety) testing for medical devices is requested by EMA and FDA since many years. However, regarding the potential of new pharmaceuticals causing allergies and/or CARPA remains a significant challenge for the industry during nonclinical development as no established safety biomarker nor meaningful, validated animal models are available up to date. During the project “IMMUNOASSAYS” Dr Fülöp proposes the development and quantitative evaluation of three promising specific safety biomarkers via ELISA technology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOASSAYS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOASSAYS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PaSION (2018)

A longitudinal assessment of treatment experience, symptoms and potential associations with biomarkers in cancer patients undergoing immune checkpoint inhibitor therapy

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More